HER2-targeted therapies in gastric cancer

Volume: 1876, Issue: 1, Pages: 188549 - 188549
Published: Aug 1, 2021
Abstract
Molecular targeted therapy of cancer has always been the focus of clinicians. Among those therapeutic targets, the human epidermal growth factor receptor-2 (HER-2) signaling pathway is one of the most popular targets for translational research in cancer. However, unlike prospect in breast cancer, HER-2 inhibitor trastuzumab is the only molecular targeted drug approved by US Food and Drug Administration (FDA) for the first-line treatment of HER-2...
Paper Details
Title
HER2-targeted therapies in gastric cancer
Published Date
Aug 1, 2021
Volume
1876
Issue
1
Pages
188549 - 188549
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.